These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15953491)

  • 1. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
    Leucht S; Busch R; Hamann J; Kissling W; Kane JM
    Biol Psychiatry; 2005 Jun; 57(12):1543-9. PubMed ID: 15953491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.
    Agid O; Kapur S; Arenovich T; Zipursky RB
    Arch Gen Psychiatry; 2003 Dec; 60(12):1228-35. PubMed ID: 14662555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
    Levine SZ; Leucht S
    Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia.
    Levine SZ; Leucht S
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):812-7. PubMed ID: 22507686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
    Welge JA; Keck PE
    Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative remission rates of schizophrenic patients using various remission criteria.
    Beitinger R; Lin J; Kissling W; Leucht S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1643-51. PubMed ID: 18616969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.
    Lambert M; Schimmelmann BG; Naber D; Eich FX; Schulz H; Huber CG; Karow A
    Pharmacopsychiatry; 2009 Nov; 42(6):277-83. PubMed ID: 19924588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atypical neuroleptics--a heterogenous group. Valuable option in acute psychoses].
    MMW Fortschr Med; 2002 May; Suppl 2():85. PubMed ID: 12070863
    [No Abstract]   [Full Text] [Related]  

  • 17. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
    Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
    Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing early prediction for antipsychotic response in schizophrenia.
    Chang YC; Lane HY; Yang KH; Huang CL
    J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.